Source comparisons
Approved comparison material connected to this topic. Only stored records are displayed.
Comparison
Topical (intact skin) 0.5%–5% 1.8–3.2% (mild dermatitis) None detected (<2 µg/dL change) Yes. 12-week trials with 6-month follow-up Safest route with decades of validation; minimal risk profile Topical (open wounds) 1%–…
Source: realpeptides.coComparison
GHK-Cu 8–24 months Injection site reaction (12%), mild erythema (8%) Copper chelation, gene expression modulation Research-grade compound (not FDA-approved as drug) Favorable. No cumulative toxicity signals in trials up…
Source: realpeptides.coComparison
GHK-Cu's safety profile has been evaluated across multiple administration routes and model systems. The table below synthesizes findings from peer-reviewed studies, regulatory assessments, and comparative peptide resear…
Source: realpeptides.co